Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
Wang ES, Montesinos P, Minden MD, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Gambacorti-Passerini C, Patkowska E, Liu S, Wu R, Philipose N, Hill JE, Gill SC, Rich ES, Tiu RV.
Wang ES, et al. Among authors: liu s.
Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586.
Blood. 2022.
PMID: 35917453
Free PMC article.
Clinical Trial.